FEATURED ARTICLES

• 6 Key Ways Real-World Data Is Advancing Colorectal Cancer Therapies

  Real-world data (RWD) is transforming Colorectal cancer (CRC) research by complementing traditional clinical trials, accelerating drug development, and improving patient outcomes.

• Timely Lab Data To Inform Outreach To Healthcare Professionals

  Learn how you can leverage a system that offers flexible data delivery formats and seamless integration into commercialization workflows while also ensuring HIPAA-compliant deidentified data for patient privacy.

• Connecting The Right Patients To The Right Trial

  Direct outreach to potential participants and communication with their healthcare providers is key to boosting trial awareness and participation, thereby achieving recruitment targets.

• 5 Ways Lab Data Can Help Commercialize Your Therapy

  In this text, we delve into five pivotal insights for leveraging lab data effectively.

• 6 Ways Lab Data Can Improve Clinical Trials

  Explore six key ways laboratory data strengthens the clinical trial process, focusing on how RWD enhances patient recruitment, accelerates screening workflows, and improves overall study outcomes.

• 6 Key Ways Real-World Data Is Accelerating Breast Cancer Therapies

  Real-world data (RWD) is increasingly vital for advancing breast cancer research, and leveraging TA datasets allows researchers and clinicians to address pressing challenges.

• 8 Key Applications Of Real-World Data In Multiple Myeloma Therapy Development

  Explore how therapeutic area (TA) datasets can be leveraged to address the challenges multiple myeloma (MM) presents in the field of hematologic malignancies.

• 5 Essential Capabilities For Decentralized Clinical Trials

  Learn how to develop and utilize a successful DCT framework, enabling your study to enhance patient access, improve data quality, and streamline study operations.

• Data-Driven Physician Engagement For Ultra-Rare Diseases

  How can an effective partnership help you to utilize advanced data analytics to address the significant challenges of clinical trials centered around ultra-rare diseases?